Recent developments highlight progress in clinical trials, commercial adoption, and financial reporting for SeaStar Medical.

• SeaStar Medical's stock gained 13% ahead of Q2 2026 results as its critical care pipeline advances [N1].
• The company reported new positive data for QUELIMMUNE therapy in pediatric acute kidney injury (AKI) patients [N4].
• SeaStar Medical exceeded 50% enrollment in its NEUTRALIZE-AKI pivotal trial for adult AKI patients [N5].
• The company completed FDA enrollment requirements for the SAVE registry in pediatric AKI patients [N6].
• SeaStar Medical published its Q1 2026 earnings transcript detailing financial and operational updates [N3].
• The company has been active in investor conferences and reported positive clinical and commercial progress in recent quarters [N7, N8].

SeaStar Medical's SCD therapy addresses a significant clinical need by modulating hyperinflammation in critically ill patients, with FDA approval for pediatric AKI and ongoing pivotal adult trials. Positive early real-world data and multiple Breakthrough Device Designations support the therapy's potential. The company's direct sales model and growing commercial hospital customer base for QUELIMMUNE indicate initial market traction. Expansion into adult indications and chronic disease settings, supported by a broad patent portfolio and manufacturing scale-up, could enhance market opportunity. Successful reimbursement strategies and partnerships may further support adoption and commercial growth.

SeaStar Medical faces substantial risks including its recurring operating losses, negative cash flows, and substantial doubt about its ability to continue as a going concern without additional financing. The company depends on successful completion of clinical trials and regulatory approvals for adult indications, which are uncertain and costly. Adoption of the SCD therapy may be limited by reimbursement challenges, supply chain dependencies, and the need for hospital clinician education. Failure to secure sufficient capital could lead to restructuring or bankruptcy, adversely impacting operations and shareholder value.

SeaStar Medical's moat is based on its proprietary SCD technology that selectively modulates activated immune cells to address hyperinflammation, a critical unmet medical need in acute and chronic organ failure. The therapy's FDA approval under HDE for pediatric AKI and multiple Breakthrough Device Designations for adult indications provide regulatory advantages. The company's patent portfolio and exclusive licensing agreements with the University of Michigan protect its intellectual property. Integration of the SCD into existing CRRT systems and the unique mechanism of action targeting activated neutrophils and monocytes differentiate it from immunosuppressive or cytokine-targeting therapies. However, the company faces challenges including clinical trial completion, regulatory approvals for adult indications, reimbursement, and capital requirements.

• Going Concern and Financing Risk: The company has recurring losses and negative cash flows with substantial doubt about its ability to continue as a going concern. Additional financing is required to fund operations and complete regulatory approvals. Failure to obtain financing may lead to restructuring or bankruptcy.
• Clinical and Regulatory Risk: Successful completion of the NEUTRALIZE-AKI pivotal trial and other clinical studies is critical for adult indications. Regulatory approvals beyond the pediatric HDE are uncertain and may require significant time and resources.
• Market Adoption and Reimbursement Risk: Adoption of the SCD therapy depends on securing reimbursement from CMS and private payors. Lack of coverage or unfavorable reimbursement could limit market penetration and commercial success.
• Supply Chain and Manufacturing Risk: The company relies on manufacturing partners and suppliers for SCD cartridges and intravenous solutions (RCA and calcium). Disruptions could adversely affect product availability and commercialization.
• Operational and Growth Management Risk: Scaling operations, managing growth, and building commercial infrastructure pose challenges. Failure to effectively manage these could delay business objectives and impact financial performance.

• SeaStar Medical Holding Corp is a commercial-stage healthcare company focused on treatments for critically ill patients with organ failure and hyperinflammation [S1].
• The company’s primary product is the Selective Cytopheretic Device (SCD), a disease-modifying device designed to neutralize overactive immune cells and stop cytokine storms causing hyperinflammation [S1].
• The SCD therapy has broad potential applications in acute and chronic kidney disease, cardiovascular, and other inflammatory diseases [S1].
• SeaStar Medical received FDA approval on February 21, 2024, under a Humanitarian Device Exemption (HDE) for its pediatric SCD therapy, branded QUELIMMUNE, for pediatric patients with acute kidney injury (AKI) due to sepsis requiring kidney replacement therapy [S1].
• The company began commercial shipments of QUELIMMUNE in July 2024 and targets top-tier pediatric medical facilities for adoption [S1].
• A post-approval patient surveillance registry (SAVE Surveillance Registry) is in place to track safety and performance metrics for QUELIMMUNE, with 50 patients enrolled as of March 4, 2026 [S1].
• Early real-world data from 21 pediatric patients in the SAVE Registry showed no device-related safety events, 76% survival at 60 days, and 71% survival at 90 days, supporting a 50% reduction in mortality compared to historical data [S1].
• SeaStar Medical is conducting a pivotal clinical trial named NEUTRALIZE-AKI to assess safety and efficacy of SCD therapy in critically ill adult patients with AKI requiring continuous renal replacement therapy (CRRT) [S1].
• As of March 13, 2026, 178 patients were enrolled in the NEUTRALIZE-AKI trial, which plans to enroll 339 patients total [S1].
• The NEUTRALIZE-AKI trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency comparing SCD plus CRRT versus CRRT alone [S1].
• The company has received six FDA Breakthrough Device Designations (BDD) covering multiple adult indications including AKI, cardiorenal syndrome awaiting LVAD implantation, hepatorenal syndrome, end stage renal disease, and systemic inflammatory response during cardiac surgery [S1].
• The SCD therapy is an extracorporeal synthetic membrane device integrated into existing CRRT systems using regional citrate anticoagulation (RCA) to create a low calcium environment that modulates activated neutrophils and monocytes [S1].
• The mechanism involves selective binding and deactivation of highly activated neutrophils and monocytes, reducing hyperinflammation without causing immunosuppression or leukopenia [S1].
• SeaStar Medical has a patent portfolio of 46 patents and 1 pending application, including exclusive licenses from the University of Michigan for commercialization in all human therapeutic indications [S1].
• The company uses a direct sales model for QUELIMMUNE in the U.S. pediatric market, having terminated a prior distribution agreement and built internal sales and marketing infrastructure [S1].
• As of December 31, 2025, 10 active commercial hospital customers had completed the IRB process and purchased QUELIMMUNE therapy, with plans for additional activations in 2026 [S1].
• SeaStar Medical is developing reimbursement strategies targeting CMS and private payors to secure coverage and payment for its SCD products, critical for adoption especially in adult indications [S1].
• The company is focused on scaling production with manufacturing partners and securing suppliers to meet anticipated demand for pediatric and adult SCD cartridges [S1].
• SeaStar Medical’s financial snapshot as of June 30, 2026, shows current assets of $8.23 million, current liabilities of $4.35 million, cash and equivalents of $51,567, a current ratio of 1.89, and a cash ratio of 0.01 [S2].
• The company reported a net loss of $3.73 million and basic EPS of -$0.91 for the quarter ended June 30, 2026 [S2].
• SeaStar Medical has experienced recurring operating losses and negative cash flows since inception, with substantial doubt about its ability to continue as a going concern without additional financing [S1, S2].
• The company’s independent auditors included an emphasis of matter paragraph regarding going concern in the 2025 financial statements [S1].
• SeaStar Medical will need to raise additional capital to fund operations and complete regulatory approval processes; failure to do so may require restructuring or reorganization under bankruptcy laws [S1, S2].
• Recent news highlights include a 13% stock gain ahead of Q2 2026 results as the critical care pipeline advances [N1], positive QUELIMMUNE data in pediatric AKI [N4], and exceeding 50% enrollment in the NEUTRALIZE-AKI pivotal trial [N5].
• The company completed FDA enrollment requirements for the SAVE registry in pediatric AKI as of March 5, 2026 [N6].
• SeaStar Medical’s Q1 2026 earnings transcript was published on May 13, 2026 [N3].
• The company has been active in investor conferences and has reported positive clinical and commercial progress in recent quarters [N7, N8].